Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Clinical Research Center For Breast Disease In Hunan Province, Changsha, China.
Front Immunol. 2024 Apr 30;15:1355887. doi: 10.3389/fimmu.2024.1355887. eCollection 2024.
Breast cancer (BC) stands out as the cancer with the highest incidence of morbidity and mortality among women worldwide, and its incidence rate is currently trending upwards. Improving the efficiency of breast cancer diagnosis and treatment is crucial, as it can effectively reduce the disease burden. Circulating tumor DNA (ctDNA) originates from the release of tumor cells and plays a pivotal role in the occurrence, development, and metastasis of breast cancer. In recent years, the widespread application of high-throughput analytical technology has made ctDNA a promising biomarker for early cancer detection, monitoring minimal residual disease, early recurrence monitoring, and predicting treatment outcomes. ctDNA-based approaches can effectively compensate for the shortcomings of traditional screening and monitoring methods, which fail to provide real-time information and prospective guidance for breast cancer diagnosis and treatment. This review summarizes the applications of ctDNA in various aspects of breast cancer, including screening, diagnosis, prognosis, treatment, and follow-up. It highlights the current research status in this field and emphasizes the potential for future large-scale clinical applications of ctDNA-based approaches.
乳腺癌（BC）是全球女性发病率和死亡率最高的癌症，其发病率目前呈上升趋势。提高乳腺癌诊断和治疗的效率至关重要，因为它可以有效减轻疾病负担。循环肿瘤 DNA（ctDNA）来源于肿瘤细胞的释放，在乳腺癌的发生、发展和转移中起着关键作用。近年来，高通量分析技术的广泛应用使 ctDNA 成为早期癌症检测、监测微小残留疾病、早期复发监测和预测治疗效果的有前途的生物标志物。基于 ctDNA 的方法可以有效地弥补传统筛查和监测方法的不足，这些方法无法为乳腺癌的诊断和治疗提供实时信息和前瞻性指导。本综述总结了 ctDNA 在乳腺癌筛查、诊断、预后、治疗和随访等各个方面的应用。它强调了该领域的当前研究现状，并强调了基于 ctDNA 的方法未来在大规模临床应用中的潜力。
